去纤维钠的适应症

It is a new drug launched in the EU in 2013, with other names: defibrinoside and defiteli. It is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). Defibrotide sodium was also awarded the title of "Orphan Drug" by the FDA and was approved for marketing in the United States in 2016.

Defibrotide sodium (defiteli) is a single-stranded oligonucleotide mixture. Preclinical tests have confirmed that it has anti-thrombotic, fibrinolytic, anti-ischemic, and anti-infective effects in vivo and in vitro.

As an injectable drug, patients must strictly follow the prescribed usage method. For the treatment of children and adults, the dose of defibrotide sodium (defiteli) is based on body weight. The recommended dose is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The minimum period of administration of defibrinated sodium is 21 days. If signs and symptoms of HVOD have not resolved after 21 days, continue defibrination until resolution of HVOD or up to a maximum of 60 days.

The use of defibrinated sodium (defiteli, defiteli) needs to be carried out by a professional doctor with treatment experience. The defibrinated sodium needs to be diluted before infusion. Patients who are allergic to any component of defibrinated sodium are prohibited from using it. Do not coadminister with other intravenous medications at the same time and in the same intravenous line. Concomitant use of defibrinated sodium and a systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding (excluding use for routine maintenance or central venous line reopening).

(Defibroside, defiteli) is relatively well tolerated during the treatment of children and adults, and can effectively prevent and treat HVOD, improving the survival rate of patients, and more and more patients are benefiting from it.